Cytokine-induced killer cell

Innate Pharma Presents New Data on Next-Generation NK Cell Engager Platform at FOCIS 2021 Annual Meeting

Retrieved on:

Thursday, June 10, 2021

Immune system, Medical specialties, Branches of biology, Lymphocytes, Clinical medicine, Natural killer cell, Cytokine-induced killer cell

This latest innovation leverages the advantages of harnessing NK cell effector functions against cancer cells and also provides proliferation and activation signals targeted to NK cells.

Key Points:

This latest innovation leverages the advantages of harnessing NK cell effector functions against cancer cells and also provides proliferation and activation signals targeted to NK cells.
This data set is built on Innates existing tri-specific NK cell engager technology, which has demonstrated potent NK cell activation, cytotoxicity and efficient control of tumor growth in preclinical models.
We are excited to introduce the new evolution of our ANKET platform at the FOCIS meeting today, said Pr.
ANKET(Antibody-based NK cell Engager Therapeutics) is Innate Pharma's proprietary platform for developing next-generation, multi-specific NK cell engagers to treat certain types of cancer.

TCR² Presentations at American Association of Cancer Research (AACR) Annual Meeting 2021 to Highlight Solid Tumor Pipeline

Retrieved on:

Wednesday, March 10, 2021

Medical specialties, Immune system, Branches of biology, Clinical medicine, Chimeric antigen receptor T cell, T cell, Cytokine-induced killer cell, Natural killer cell

Abstracts can be found at www.aacr.org and include the following e-poster presentations below.

Key Points:

Abstracts can be found at www.aacr.org and include the following e-poster presentations below.
This e-poster presentation will highlight fratricide-resistant CD70-directed TRuC-T cells, which demonstrated an improved memory phenotype and significant anti-tumor efficacy in multiple xenograft mouse models with no evidence of in vivo fratricide.
In preclinical studies, TRuC-T cells have demonstrated superior anti-tumor activity compared to chimeric antigen receptor T cells (CAR-T cells), while secreting lower levels of cytokine release.
Any forward-looking statement included in this press release speaks only as of the date on which it was made.

IN8bio Presents Gamma-Delta T Cells as Cancer Therapeutics at the ESMO Targeted Anticancer Therapies Virtual Conference 2021

Retrieved on:

Tuesday, March 2, 2021

Branches of biology, Medical specialties, Immune system, Biology, Immunology, Lymphocytes, T cells, Stem cells, Natural killer cell, Cytokine-induced killer cell

Gamma-delta T cells are a specialized population of T cells that possess unique properties, including the ability to differentiate between healthy and diseased tissue.

Key Points:

Gamma-delta T cells are a specialized population of T cells that possess unique properties, including the ability to differentiate between healthy and diseased tissue.
Research has demonstrated that both higher levels of gamma-delta T cells and the presence of infiltrating gamma-delta T cells are correlated with better survival outcomes.
Chemotherapy, a mainstay of solid tumor treatment, depletes and damages gamma-delta T cells, limiting their ability to seek and kill tumor cells.
Topline Phase 1 results are expected to be presented at a major medical conference in the second half of 2021.

New Preclinical Data being Presented at SITC Underscore Promising Combinations of Affimed’s AFM13 and Cytokine-Activated Natural Killer Cells

Retrieved on:

Monday, November 9, 2020

Branches of biology, Medical specialties, Clinical medicine, Lymphocytes, Immune system, Natural killer cell, CD30, Lymphoma, Cytokine-induced killer cell, Tumor microenvironment

The current set of preclinical in vitro and in vivo data demonstrate the increased efficacy of AFM13-preloaded cord blood-derived NK cells towards CD30-positive tumor cells, said Arndt Schottelius, M.D.

Key Points:

The current set of preclinical in vitro and in vivo data demonstrate the increased efficacy of AFM13-preloaded cord blood-derived NK cells towards CD30-positive tumor cells, said Arndt Schottelius, M.D.
AFM13-preloaded cNK cells from healthy donors exhibited superior responses versus those from Hodgkin lymphoma patients suggesting that the source of NK cells impacts tumor cell killing.
IL-12, IL-15, and IL-18-induced ML NK cells exhibited enhanced killing of CD30+ lymphoma cells when directed by AFM13, compared to cNK cells.
Similarly, AFM13 combined with cord-blood expanded NK cells that were pre-activated with IL-12, IL-15 and IL-18 also exhibited tumor cell killing compared to expanded cb NK cells.

Artiva Biotherapeutics and Affimed Announce Platform-to-Platform R&D Collaboration for Targeted Off-the-Shelf NK Cell Therapies

Retrieved on:

Thursday, November 5, 2020

Branches of biology, Biology, Medical specialties, Immune system, Lymphocytes, Natural killer cell, Cell biology, Biotechnology, Cell therapy, Epidermal growth factor receptor, Chimeric antigen receptor T cell, Cytokine-induced killer cell

Under the agreement, Affimeds ICE molecules targeting EGFR and other undisclosed targets will be combined with Artivas GMP-grade allogeneic NK cells during the cell manufacturing process.

Key Points:

Under the agreement, Affimeds ICE molecules targeting EGFR and other undisclosed targets will be combined with Artivas GMP-grade allogeneic NK cells during the cell manufacturing process.
The resulting cryopreserved, off-the-shelf, targeted allogeneic NK cell products will be assessed for anti-tumor activity and development potential.
Artivas AB-101 is a universal NK cell therapy for use in combination with monoclonal antibodies or novel modalities such as NK cell engagers.
Artivas pipeline of universal and targeted NK cell therapies leverages the innate anti-tumor biology and safety features of NK cells.

Novocellbio in Korea Confirms NOVO-NK’s Promising Antiviral Effects Against COVID-19

Retrieved on:

Monday, August 10, 2020

View the full release here: https://www.businesswire.com/news/home/20200810005002/en/

Key Points:

View the full release here: https://www.businesswire.com/news/home/20200810005002/en/
Novocellbio conducted experiments using NOVO-NK, an autologous natural killer cell treatment at Seoul National University College of Medicine.
It was confirmed that the autologous natural killer cell treatment agent NOVO-NK killed the human-derived COVID-19 coronavirus.
In this experiment, monkey kidney cells (VeroE6 cells) infected with the COVID-19 coronavirus (SARS-CoV-2) were treated with NOVO-NK cells.
Novocellbio Co., Ltd. plans to further develop anti-cancer, autoimmune disease, and viral treatment through continuous research and development.

Simcha Therapeutics Shares Data at AACR Annual Meeting Highlighting Potent Preclinical Efficacy of Decoy-Resistant IL-18 Cytokine

Retrieved on:

Thursday, June 25, 2020

NK cells quickly become exhausted and lose efficacy when confronted with tumor cells deficient in MHC Class 1.

Key Points:

NK cells quickly become exhausted and lose efficacy when confronted with tumor cells deficient in MHC Class 1.
Single cell RNA sequencing and flow cytometry revealed that DR-18 promoted functional maturation of highly proliferative NK cells.
These results highlight DR-18s ability to remodel the intratumoral ecosystem to encourage the proliferation of potent anti-tumor effector cells.
Simcha Therapeutics uses directed evolution to engineer novel cytokines designed to unlock the precision and power of the immune system.

Xencor Presents Data from Four Preclinical XmAb® 2+1 Bispecific Antibody and Cytokine Programs at AACR Virtual Annual Meeting II

Retrieved on:

Monday, June 22, 2020

Research, Biotechnology, Other Health, Health, Pharmaceutical, General Health, Other Science, Science, Oncology, Medical specialties, Medicine, Immunology, Monoclonal antibodies, Immune system, Bispecific monoclonal antibody, Antibody, Cytokine-induced killer cell

Poster presentations and audio descriptions are available to registrants of the AACR Virtual Annual Meeting .

Key Points:

Poster presentations and audio descriptions are available to registrants of the AACR Virtual Annual Meeting .
This selectivity and potency tuning of T-cell activation may provide for higher efficacy and tolerability compared to other bispecific antibody formats.
"We have also presented data from our IL-12-Fc cytokine program, which builds off of our prior work with IL-15 and IL-2.
Additional data presented on XmAb 2+1 PSMA x CD3 bispecific antibody candidates and XmAb30819, a first-in-class XmAb 2+1 ENPP3 x CD3 bispecific antibody, demonstrated strong reversal of tumor growth in human-cell engrafted mouse models of disease.

NKMax America Receives FDA Clearance of IND for Phase I/2a Trial of their Natural Killer Cell Therapy (SNK01) in Combination with Trastuzumab or Cetuximab for the Treatment of Advanced/Metastatic HER2- or EGFR- Expressing Cancers

Retrieved on:

Tuesday, June 2, 2020

Immune system, Medical specialties, Medicine, Branches of biology, Lymphocytes, Cancer treatments, Natural killer cell, CD16, Antibody-dependent cellular cytotoxicity, Cytokine-induced killer cell

The company plans to initiate a Phase 1/2a open-label, multi-center trial (Study SNK01-102) to evaluate the safety and anti-tumor activity of its expanded autologous natural killer cells in combination with trastuzumab or cetuximab in third quarter of this year.

Key Points:

The company plans to initiate a Phase 1/2a open-label, multi-center trial (Study SNK01-102) to evaluate the safety and anti-tumor activity of its expanded autologous natural killer cells in combination with trastuzumab or cetuximab in third quarter of this year.
Our preclinical research highlights our ability to exponentially increase NK cell cytotoxicity and generate high CD16 expression to optimize the ADCC pathway helping to overcome these limitations.
NKMax America Inc. is a clinical stage biotechnology company dedicated to restoring and enhancing overall immune integrity.
Our proprietary natural killer cell expansion and activation technology achieves infinite fold natural killer cell expansion with greatly enhanced cytotoxicity across its autologous, allogenic, and CAR-NK products which are all derived from peripheral blood.

NKMax America to Present at Immuno-Oncology Summit Europe 2020

Retrieved on:

Monday, March 9, 2020

Medical specialties, Medicine, Immune system, Branches of biology, Natural killer cell, Cytotoxicity, Immune checkpoint, Cytokine-induced killer cell, Cancer immunotherapy

He will highlight NKMax Americas proprietary natural killer cell expansion/activation technology and clinical experience in ADCC and immune checkpoint-based therapy.

Key Points:

He will highlight NKMax Americas proprietary natural killer cell expansion/activation technology and clinical experience in ADCC and immune checkpoint-based therapy.
NKMax America Inc. is a clinical stage biotechnology company dedicated to restoring and enhancing overall immune integrity.
Our proprietary natural killer cell expansion and activation technology achieves infinite fold natural killer cell expansion with greatly enhanced cytotoxicity across its autologous, allogenic, and CAR-NK products which are all derived from peripheral blood.
The company and its commercially licensed GMP facility are headquartered in Santa Ana, California, USA.